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Cognitive Interventions and Nutritional
Supplements (The CINS Trial)
A Randomized Controlled, Multicenter Trial Comparing a Brief Intervention With Additional
Cognitive Behavioral Therapy, Seal Oil, and Soy Oil for Sick-Listed Low Back Pain Patients
Silje E. Reme, PhD,,jj, Torill H. Tveito, PhD,,zzzz Anette Harris, PhD,y Stein Atle Lie, PhD,jjjjjj
Astrid Grasdal, PhD,z Aage Indahl, MD, PhD,y,{{ Jens Ivar Brox, MD, PhD,jj Tone Tangen, MD, PhD,§
Eli Molde Hagen, MD, PhD,§§ Sigmund Gismervik, MD,,zz Arit Ødega˚rd, MD, Livar Frøyland, PhD,{
Egil A. Fors, MD, PhD,zz,jjjj Trudie Chalder, PhD,yy and Hege R. Eriksen, PhD,yyyy
Study Design. A randomized controlled trial.
Objective. The aim of this study was to evaluate whether a
tailored and manualized cognitive behavior therapy (CBT) or nutri-
tional supplements of seal oil and soy oil had any additional benefits
over a brief cognitive intervention (BI) on return to work (RTW).
Summary of Background Data. Brief intervention programs
are clinically beneficial and cost-effective for patients with low
back pain (LBP). CBT is recommended for LBP, but evidence on
RTW is lacking. Seal oil has previously been shown to have a
possible effect on muscle pain, but no randomized controlled
trials have so far been carried out in LBP patients.
Methods. Four hundred thirteen adults aged 18 to 60 years
were included. Participants were sick-listed 2 to 10 months due
to LBP. Main outcome was objectively ascertained work
participation at 12-month follow-up. Participants were randomly
assigned to BI (n¼100), BI and CBT (n¼103), BI and seal oil
(n¼105), or BI and soy oil (n¼105). BI is a two-session
cognitive, clinical examination program followed by two booster
sessions, while the CBT program is a tailored, individual, seven-
session manual-based treatment.
Results. At 12-month follow-up, 60% of the participants in the
BI group, 50% in the BI and CBT group, 51% in the BI and seal
oil group, and 53% in the BI and soy oil group showed reduced
sick leave from baseline, and had either partly or fully RTW.
The differences between the groups were not statistically
significant (x2¼2.54, P¼0.47). There were no significant
differences between the treatment groups at any of the other
follow-up assessments either, except for a significantly lower
sick leave rate in the BI group than the other groups during the
first 3 months of follow-up (x2¼9.50, P¼ 0.02).
Conclusion. CBT and seal oil had no additional benefits over a
brief cognitive intervention on sick leave. The brief cognitive
intervention alone was superior in facilitating a fast RTW.
Key words: absenteeism, brief intervention, chronic low back
pain, cognitive behavior therapy, Oswestry, seal oil, sick leave.
Level of Evidence: 2
Spine 2016;41:1557–1564
L
ow back pain (LBP) is common in the general popu-
lation and is the most expensive cause of work-related
disability.1,2 It is also the health condition that causes
most years lived with disability.3 In Norway, musculoske-
letal disorders account for about 40% of the long-term sick
leave, with LBP as the single most common diagnosis.4
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Whether a LBP incident results in sick leave or not depends
on complex individual, psychosocial, and work organiz-
ational factors.2
Brief intervention programs are considered clinically
beneficial and cost-effective for patients with subacute
LBP.5 The prognosis for patients with LBP is good in the
acute stage,6 but poorer when the condition endures.2,7–9
The treatment principles applied in the present study follow
the evidence-based guidelines for the treatment of chronic
LBP, developed in Europe.10 The recommended treatments
include conservative treatments such as cognitive behavior
therapy (CBT) and brief educational interventions (BI).
While the evidence points to these as effective treatments,
many of the studies are at risk of bias,11 and effect sizes are
modest.12
Seal oil is a marine oil that is relatively rich in the omega-3
polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid
(EPA; 20:5n-3), docosapentaenoic acid (DPA; 22:5n-3), and
docosahexaenoic acid (DHA, 22:6n-3). There is little sci-
entific documentation of the medical effect of seal oil, apart
from an indication of a positive effect on muscle pain.13–16
A possible mechanism for these findings involve the effect of
lowering the ratio of n-6 to n-3 PUFAs to suppress n-6
eicosanoids and proinflammatory cytokines, which may
provide pain relief in chronic inflammatory disorders, as
western diet is dominated by linoleic acid and arachidonic
acid.17 Given these preliminary findings, testing a possible
effect of seal oil in LBP patients is an interesting experiment.
The Cognitive Interventions and Nutritional Supple-
ments (CINS) trial was designed as a randomized controlled
trial18 to compare CBT when added to BI, with seal oil and
soy oil when added to BI, with BI alone, in patients sick-
listed for unspecific LBP.
MATERIALS AND METHODS
This was a four-arm, multicenter, randomized, double-
blind, placebo-controlled trial conducted in Norway. The
study took place at four different clinics from February 2008
to August 2010. The full protocol for the trial is published
elsewhere.18 The participants were randomized to BI only,
BI and CBT, BI and seal oil, or BI and soy oil. For readability
purposes, the four arms will be referred to as BI, CBT, seal
oil, and soy oil hereon.
Recruitment Procedure
Eligible participants were aged 20 to 60 years and sick-listed
2 to 10 months for LBP. The Norwegian Labour and
Welfare Administration sent a letter of invitation to eligible
participants. Those who responded to the invitation
(n¼2200) were screened by telephone and excluded if they
did not fulfill the inclusion criteria or could not be reached
(n¼1563). Eligible patients (n¼637) were referred to the
clinic for inclusion in the trial.
Inclusion and Exclusion
Inclusion criteria required receiving at least 50% sickness
compensation for one of the following International
Classification of Primary Care (ICPC) diagnoses: L02 (back
symptom/complaint), L03 (low back symptom/complaint),
L84 (back syndrome without radiating pain), or L86 (back
syndrome with radiating pain). Exclusion criteria were
pregnancy, hemophilia, osteoporosis, recent back trauma,
serious psychiatric disorders (using The Mini-International
Neuropsychiatric Interview), not fluent in Norwegian,
debilitating cardiovascular disease, anticoagulation treat-
ment, and ongoing insurance issue for LBP or related
conditions.
Interventions
Both BI and CBT followed detailed treatment manuals
written for the trial. All CBT treatment sessions were
audiotaped, and independent raters successively evaluated
a random selection of the tapes using a modified Norwegian
version of the Cognitive Therapy Adherence and Compe-
tence Scale (CTACS).19 Fifteen percent of the sessions were
double-rated by two experienced CBT therapists to test for
inter-rater reliability.
BI is a brief cognitive, clinical examination program
based on a noninjury model addressing pain and fear-
avoidance, where return to normal activity and work is
the main goal. BI also includes a follow-up session with a
physiotherapist, involving an educational and a behavioral
part. Patients were additionally offered two short booster
sessions.
The CBT involved seven sessions of individual CBT over
a period of 2 to 3 months. The CBT builds on the message
contained in BI, where the aim was to help patients change
cognitive and behavioral factors assumed to be partly
responsible for the maintenance of symptoms and disability.
Patients randomized to nutritional supplements received
commercially available seal or soy oil for the same duration
as the CBT treatment, in a double-blind, randomized, con-
trolled design. Oils were administered as 20 capsules daily.
Testing of the oils before the intervention showed that
vitamin A, that is, sum retinol (13-, 11-, 9-cis) and all trans
retinol, that is, A1 and 3,4 didehydro-all-trans retinol (A2) in
both oils were below 0.28 mg/kg. Vitamin D3 content in
daily soy oil and seal oil dosages were 1 and 0mg, respect-
ively. The antioxidant D-alpha-tocopherol was added in the
case of seal oil, giving a vitamin E (alpha-tocopherol) con-
tent in seal oil and soy oil of 85.4 and 16.6 g/100 g, respect-
ively. The seal oil contained 56.6 g/100 g monounsaturated
fatty acids, which are less prone to lipid peroxidation than
PUFAs, and the oil has no known major adverse effects.15,16
Soy oil is common in the diet in the western world and is
considered a placebo in this trial. Both oils were approved
according to current legislations on contaminants and
relevant quality standards.
Outcomes
The primary outcome was sick leave, obtained from
national registry data at 12 months, which was operation-
alized as (1) transition from full-time sick leave to partial
sick leave or full-time return to work (RTW), or (2)
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transition from partial sick leave to a lower gradient of sick
leave or full-time RTW.
Secondary outcome measures included Subjective Health
Complaints (SHC),20 Oswestry Disability Index to assess
pain-related function,21,22 and Hospital Anxiety and
Depression Scale (HADS)23 to assess psychological distress.
In addition, back pain intensity over the last 14 days and
pain during activity and rest over the last week (both
measured on a numeric rating scale from 0 to 10) were
used to measure pain complaints, and the health index from
EQ5D was used to measure health-related quality of life.24
Sample Size
The sample size calculations were based on data from Hagen
et al.25 All calculations were based on a power of 80% and a
significance level of 5%, and showed that the total number
of participants needed was 97 in each treatment arm
(N¼388). For details, see.18
Randomization and Blinding
Randomization and treatment allocation procedures were
concealed and done according to a computer generated
randomization list stratified by clinic and gender. A central
telephone randomization system was used. At each of the
participating clinics, a research assistant, not involved in the
treatment, called the research unit to be informed about
allocation. The allocation code, including details of block
size, was not revealed to the researchers or the clinicians
until recruitment, data collection, and laboratory analyses
were complete. Block size varied between 8 and 24. For
those participants allocated to nutritional supplementation,
the clinics provided blinded boxes, containing capsules with
either seal oil or soy oil. The capsules with placebo (soy oil)
oil were matched to seal oil for taste, color, and size.
All researchers, clinicians, and participants were blinded
to treatment allocation of individual participants for the
nutritional supplements, and all researchers were blinded to
group assignment.
Statistical Methods
The primary outcome was based on crude rates of partici-
pants with reduced sick leave in the four groups. For the
secondary outcomes, we performed analyses with inverse
probability weights26 to account for possible attrition bias.
Analyses adhered to the ‘‘intention-to-treat’’ principle. Per-
protocol analyses were also performed.
According to the analysis plan,18 Cox-proportional haz-
ards models was intended used to measure the risk for
transition between different states of disbursement. In
addition, number needed to treat was planned to be
assessed. However, both these analyses presuppose signifi-
cant treatment effects, and were therefore not performed.
Sufficient adherence in the CBT treatment was defined as
attending at least four out of seven sessions, or successful
completion due to recovery and/or RTW. Adherence to the
oils was measured through completed oil diaries and/or
follow-up phone calls two and eight weeks after starting
the treatment. Sufficient adherence was here defined as oral
confirmation of compliance from the patients on the phone,
or indications of full compliance, or only occasional omis-
sions, from the diaries.
RESULTS
Of 637 patients screened for eligibility, 63 patients were not
eligible and 160 patients were randomized to two other
substudies that will be presented elsewhere. The 414
patients included in the CINS-trial were treated between
February 2008 and August 2010. One patient was excluded
after randomization due to serious psychopathology, leav-
ing a total of 413 participants.
See Figure 1 for details about drop-out and loss to follow-
up. All participants received and complied with the BI.
On the basis of diaries and the follow-up phone calls, the
following side effects were reported: gastrointestinal dis-
comfort, including regurgitation, nausea, flatulence,
stomach ache, and discomfort (n¼30); difficulties swallow-
ing the capsules (n¼11); and ‘‘other’’ side effects, including
sleep problems, dizziness, weight gain, and itching (n¼7).
No serious side effects were reported.
To assess care providers’ adherence to the treatment
manuals, an assessor evaluated every fifth BI and CBT
session independently. The evaluations revealed overall high
adherence to both interventions. The risk of contamination
was accounted for by asking participants about cointerven-
tions (for CBT) and diet (for oils), neither of which indicated
any contamination of concern.
There was an equal gender distribution in patients referred
and included in the trial. Mean age was 44.8 years, and the
mean duration of back pain was 12.5 years (Table 1).
Participants’ preferences were highest for CBT [n¼185
(56%)], followed by BI [n¼106 (35%)], seal oil [n¼70
(23%)], and soy oil [n¼27 (9%)].
Of the participants who responded to the self-reported
question of treatment satisfaction (n¼217, 53%), most
were satisfied (a little, some, or very satisfied) with the
treatment they had received at 3 months follow-up
(n¼135, 62%). The highest satisfaction was within the
group receiving CBT, where 75% reported that they were
somewhat or very satisfied, followed by 66% in seal oil,
55% in soy oil, and 52% in BI. Only 4% reported very low
satisfaction with the treatment.
To test for blinding, participants were asked their best
guess on what oil they had received. At 3 months follow-up,
41% of the participants who had received soy oil did not
know what they had received, 21% guessed they had
received soy oil, and 38% believed they had received seal
oil. Forty-one percent of the participants who had received
seal oil could not say which treatment they had received,
22% guessed they had received soy oil, and 37% guessed
they had received seal oil. Blinding index in the seal oil group
was 0.15; 95% confidence interval (CI), 0.04 to 0.35,
while blinding index in the soy oil group was 0.16;
95% CI, 0.35 to 0.02.
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Figure 1. Flow chart.
TABLE 1. Baseline Characteristics of Participants (n¼413)
BI (n¼100) CBT (n¼103) Seal Oil (n¼105) Soy Oil (n¼105)
Continuous
Variables Mean (SD) Mean (SD) Mean (SD) Mean (SD) P
Age 44.8 (9.7) 44.2 (8.8) 44.2 (10.3) 42.9 (9.7) 0.57
Duration of back
pain (yrs)
12.5 (11.3) 10.1 (9.7) 10.0 (10.3) 10.9 (10.8) 0.37
Categorical variables n (%) n (%) n (%) n (%)
Gender (women) 56 (56.0) 56 (54.4) 55 (52.4) 50 (47.6) 0.65
Civil status
Married/cohabitant 71 (73.9) 70 (70.0) 74 (73.3) 76 (74.4)
Single/widow/
divorced
25 (26.1) 30 (30.0) 27 (26.7) 26 (25.6) 0.89
Education
Primary school
(1–12 yrs)
60 (63.2) 62 (62.6) 68 (68.0) 61 (59.8)
University/college 29 (30.5) 32 (32.3) 27 (27.0) 32 (31.4)
Other 6 (6.3) 5 (5.1) 5 (5.0) 9 (8.8) 0.85
HADS
Depression (score
8)
15 (15.5) 13 (13.1) 17 (16.8) 18 (17.6) 0.83
Anxiety (score 8) 17 (17.5) 16 (16.2) 23 (22.8) 25 (24.5) 0.39
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Primary Outcome Measure
At 12 months follow-up, 60% in the BI group, 50% in the
CBT group, 51% in the seal oil group, and 53% in the soy
oil group showed reduced sick leave from baseline, and
had either partly or fully returned to work. There were
no significant differences between the treatment groups
(Table 2).
There were no significant differences between the treat-
ment groups at any of the other follow-up assessments either,
except for the first three months of follow-up (Table 2 and
Figure 2). Pairwise comparisons showed that the significant
difference in all cases involved a lower sick leave rate in the BI
group than the other groups.
Furthermore, a comparison of full RTW (i.e., not receiv-
ing any sickness benefits) was also conducted at 12 months
follow-up. The results showed 56% full RTW in the BI
group, 47% in the CBT group, 51% in the seal oil group,
and 48% in the soy oil group. There were no significant
differences between the treatment groups.
Per-protocol analyses were also conducted. They showed
the same as intention-to-treat, with no significant differ-
ences between the treatments at any of the follow-ups.
Secondary Outcome Measures
For the secondary outcome measures, there were few signifi-
cant differences between the treatments. Only three signifi-
cant differences were detected, all in favor of the CBT group;
less gastrointestinal complaints at 6 months, and lower back
pain intensity and pain during activity at 12 months (Table 3).
DISCUSSION
The main results in this study showed that neither CBT nor
seal oil had any additional benefits over a brief cognitive
intervention (BI) on any primary nor secondary outcomes,
except for a possible small effect of CBT on pain intensity
and gastrointestinal complaints. In fact, the BI alone turned
out to be superior in facilitating a fast RTW than the
other groups.
The main strength of the study is the multicenter RCT
design with complete data for the primary outcome through
the use of registry data. The problem of loss to follow-up
was therefore eliminated for the primary outcome, though
remained for secondary outcomes. Another key strength
was staff adherence to the BI and CBT protocol. This was
carefully monitored through audiotapes and revealed satis-
factory adherence with no major deviations. The blinding
of the two nutritional supplement treatments further
appeared to be successful according to the blinding index,
TABLE 2. Differences in Proportions Between the Four Treatment Groups in Increased RTW at Each
Month of Follow-up up Until 12 mo
ITT (Intention-
to-treat), mo
BI BI and CBT BI and Seal Oil BI and Soy Oil
x
2
df P# % # % # % # %
0–1 36 36 18 18 14 13 23 22 17.23 3 <0.01
0–2 49 49 40 39 31 30 38 36 8.48 3 0.04
0–3 60 60 47 46 43 41 44 42 9.50 3 0.02
0–4 64 64 49 48 51 49 52 50 7.32 3 0.06
0–5 63 63 59 57 54 51 62 59 2.93 3 0.40
0–6 61 61 61 59 58 55 56 53 1.57 3 0.67
0–7 58 58 60 58 56 53 56 53 0.96 3 0.81
0–8 58 58 63 61 55 52 57 54 1.94 3 0.59
0–9 53 53 61 59 54 51 57 54 1.42 3 0.70
0–10 57 57 55 53 55 52 57 54 0.48 3 0.92
0–11 59 59 59 57 57 54 53 51 1.75 3 0.63
0–12 60 60 51 50 54 51 56 53 2.54 3 0.47
The bold values are used to indicate statistical significant differences.
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Figure 2. Increase in return to work from baseline up until 12
months follow-up.
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TABLE 3. Estimated Marginal Mean Values for the Secondary Outcomes at the 3 Follow-up Periods
ITT
BI Mean
(95% CI)
BI and CBT
Mean (95% CI)
BI and Seal Oil
Mean (95% CI)
BI and Soy Oil
Mean (95% CI) Fy P
Back pain (last 14 d)
Baseline 6.48 (6.14–6.42) 6.32 (5.92–6.72) 6.73 (6.37–7.09) 6.52 (6.15–6.89) 0.84 0.48
Baseline 6.35 (5.73–6.98) 5.76 (4.94–6.57) 6.50 (5.95–7.05) 6.40 (5.85–6.94) 1.11 0.35
3 mo 5.65 (4.92–6.38) 5.23 (4.50–5.95) 5.89 (5.29–6.50) 5.08 (4.52–5.64) 1.47 0.22
6 mo 4.73 (4.00–5.46) 4.60 (3.79–5.42) 5.22 (4.61–5.84) 4.82 (4.19–5.45) 0.61 0.61
12 mo 5.59 (4.98–6.21) 4.42 (3.71–5.14) 5.67 (5.10–6.25) 5.06 (4.39–5.73) 2.92 0.03
Pain during activity (last wk)
Baseline 6.10 (5.72–6.49) 5.67 (5.19–6.15) 6.36 (6.00–6.72) 5.97 (5.53–6.41) 1.88 0.13
Baseline 5.66 (4.96–6.35) 4.78 (3.80–5.76) 6.29 (5.81–6.76) 6.00 (5.35–6.65) 3.42 0.02
3 mo 5.70 (5.01–6.40) 4.92 (4.19–5.65) 5.95 (5.28–6.61) 4.87 (4.22–5.51) 2.53 0.06
6 mo 4.74 (4.05–5.43) 4.19 (3.32–5.06) 4.77 (4.15–5.39) 4.25 (3.55–4.94) 0.72 0.54
12 mo 5.28 (4.68–5.88) 3.96 (3.22–4.70) 5.12 (4.50–5.73) 4.35 (3.73–4.96) 3.44 0.02
Pain during rest (last wk)
Baseline 4.05 (3.59–4.51) 3.67 (3.19–4.15) 4.36 (3.91–4.80) 3.83 (3.39–4.27) 1.69 0.17
Baseline 3.63 (2.85–4.40) 3.48 (2.64–4.33) 4.07 (3.46–4.69) 3.80 (3.09–4.51) 0.49 0.69
3 mo 3.79 (3.17–4.40) 3.53 (2.87–4.19) 3.75 (3.09–4.41) 3.39 (2.82–3.96) 0.38 0.77
6 mo 2.99 (2.36–3.62) 3.19 (2.44–3.93) 3.35 (2.71–3.99) 2.81 (2.16–3.45) 0.51 0.68
12 mo 3.82 (3.17–4.48) 3.36 (2.66–4.05) 3.30 (2.78–3.83) 2.93 (2.36–3.49) 1.38 0.25
Pain-related function (ODI)
Baseline 28.1 (25.5–30.6) 29.2 (26.7–31.8) 29.9 (27.6–32.2) 29.7 (27.4–32.0) 0.44 0.72
Baseline 28.6 (23.8–33.5) 29.3 (24.8–33.8) 28.3 (25.2–31.4) 28.5 (24.9–32.1) 0.05 0.99
3 mo 24.6 (20.8–28.4) 24.9 (20.6–29.1) 25.4 (22.1–28.8) 23.1 (19.6–26.6) 0.31 0.82
6 mo 20.6 (16.3–24.9) 20.9 (15.9–26.0) 21.5 (18.4–24.6) 23.2 (19.1–27.3) 0.28 0.84
12 mo 22.3 (18.7–25.9) 19.2 (15.2–23.2) 21.7 (18.3–25.2) 20.5 (16.7–24.4) 0.51 0.68
Anxiety symptoms (HADS)
Baseline 4.85 (4.10–5.59) 4.98 (4.21–5.74) 4.72 (4.05–5.38) 5.28 (4.57–5.99) 0.45 0.72
Baseline 4.84 (3.61–6.08) 4.37 (3.31–5.44) 4.36 (3.32–5.40) 4.30 (3.36–5.24) 0.21 0.89
3 mo 4.39 (3.13–5.64) 4.60 (3.67–5.52) 4.36 (3.41–5.32) 3.88 (2.87–4.89) 0.37 0.78
6 mo 3.94 (2.64–5.24) 3.38 (2.51–4.24) 3.92 (2.90–4.94) 3.77 (2.82–4.72) 0.29 0.83
12 mo 4.30 (3.17–5.44) 3.32 (2.53–4.11) 4.47 (3.46–5.48) 4.00 (3.04–4.95) 1.27 0.28
Depressive symptoms (HADS)
Baseline 3.92 (3.19–4.64) 3.96 (3.30–4.63) 3.88 (3.24–4.52) 4.35 (3.69–5.02) 0.42 0.74
Baseline 3.47 (2.28–4.66) 3.31 (2.26–4.36) 2.91 (1.99–3.82) 3.53 (2.58–4.48) 0.34 0.79
3 mo 3.44 (2.46–4.43) 3.40 (2.59–4.22) 3.42 (2.44–4.40) 3.42 (2.44–4.40) 0.00 0.99
6 mo 3.12 (2.08–4.16) 2.28 (1.45–3.12) 2.94 (2.13–3.76) 3.61 (2.49–4.74) 1.28 0.28
12 mo 3.17 (2.19–4.15) 2.71 (2.04–3.37) 3.47 (2.50–4.44) 3.34 (2.45–4.23) 0.74 0.53
Musculoskeletal complaints (SHC)
Baseline 8.37 (7.49–9.25) 8.45 (7.56–9.34) 8.72 (7.87–9.56) 8.44 (7.56–9.33) 0.12 0.95
Baseline 8.04 (6.43–9.65) 8.12 (6.75–9.48) 8.52 (7.24–9.81) 8.83 (7.44–10.2) 0.28 0.84
3 m 7.06 (5.87–8.26) 6.88 (5.46–8.30) 7.50 (6.29–8.71) 7.33 (6.18–8.49) 0.18 0.91
6 mo 7.26 (5.84–8.67) 6.49 (4.92–8.05) 7.15 (5.89–8.40) 7.97 (6.68–9.26) 0.71 0.55
12 mo 6.60 (5.58–7.61) 6.34 (5.20–7.48) 6.98 (5.85–8.11) 7.29 (5.99–8.59) 0.47 0.71
Pseudoneurological complaints (SHC)
Baseline 4.46 (3.76–5.16) 4.54 (3.80–5.29) 4.73 (4.05–5.40) 4.67 (4.01–5.34) 0.12 0.95
Baseline 4.12 (3.16–5.08) 4.10 (2.87–5.33) 3.85 (2.79–4.91) 4.93 (3.88–5.99) 0.89 0.45
3 mo 3.80 (2.93–4.66) 3.70 (2.78–4.61) 3.86 (3.12–4.59) 4.14 (3.05–5.23) 0.13 0.94
6 mo 3.97 (2.91–5.03) 2.67 (1.80–3.54) 3.67 (2.71–4.62) 4.52 (3.37–5.66) 2.46 0.06
12 mo 3.80 (3.01–4.58) 3.28 (2.58–3.98) 3.76 (2.90–4.62) 3.95 (2.93–4.97) 0.53 0.66
Gastrointestinal complaints (SHC)
Baseline 2.29 (1.74–2.83) 2.11 (1.59–2.62) 2.27 (1.75–2.80) 2.37 (1.85–2.90) 0.18 0.91
Baseline 2.23 (1.18–3.28) 1.69 (0.88–2.49) 1.92 (1.14–2.71) 2.65 (1.89–3.41) 1.07 0.37
3 mo 2.33 (1.57–3.09) 1.59 (1.06–2.12) 2.58 (1.81–3.35) 2.44 (1.48–3.41) 1.95 0.12
6 mo 2.45 (1.55–3.36) 1.22 (0.77–1.66) 2.26 (1.50–3.03) 2.43 (1.64–3.21) 4.20 0.01
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and compliance was relatively high for both CBT and
nutritional supplements. The low participation rate is,
however, a weakness of the study. Of the many invitations
sent out, only 414 ended up participating in the trial. We
have no information about the nonresponders and do not
know how many of them would fulfill the selection criteria,
although we expect a considerable amount to be noneligible
based on the major drop in sick leave at three months.9
Nevertheless, we cannot rule out a possible selection bias
that could have influenced the representativeness of our
study population. Furthermore, as the unique Norwegian
system offers 100% sickness compensation from day one up
until a year, the LBP-related sick leave could be a con-
founder in and of itself, acting as a vicarious motive for
other problems and concerns that do not qualify for sick-
ness compensation. Our data did indeed show that about
one-third of the participants reported that pain was not
their main problem.27
The lack of an additional RTW effect of the CBT was
counter to our hypothesis. In a similar trial from UK, group
CBT resulted in sustainable and cost-effective improvements
in disability and pain.28 This was contrary to our findings
and raise the question of whether the format of treatment
delivered (group vs. individual) could be influential. How-
ever, our results are in line with the previous trial by Indahl
et al.,29 and Karjalainen et al.,30 showing that BIs are as
effective or even more effective than longer interventions.
The results are also in line with earlier studies showing equal
effect between extensive multimodal CBT and ordinary
treatment by the general practitioner.31 Extensive multi-
modal CBT seems to be effective only when given to patients
with poor prognosis.32
Participants receiving CBT reported the highest treat-
ment satisfaction, and the trend on secondary outcomes
points toward superiority of the CBT. This might have been
demonstrated more clearly with a larger sample size. The
results on RTW, however, were less promising. The reasons
for this may be many. First, it is difficult to outperform an
already established effective intervention whose main aim is
rapid RTW. Second, the CBT was not delivered by experi-
enced CBT therapists, which may have influenced the
results. And finally, one might speculate whether the purely
individual focus of the CBT may have been too narrow, and
that combining a patient-directed and workplace-directed
intervention might have improved the outcome.33
The lack of additional effects of seal oil on symptom
reduction was also counter to our hypothesis.13–16 The
trend on the secondary outcomes points in the rather oppo-
site direction, namely that the patients receiving seal oil were
worse off on several pain-related outcomes compared with
placebo and the other treatment arms. Furthermore, in
terms of RTW, there is a consistently lower RTW trend
for the patients receiving nutritional supplements, particu-
larly the seal oil group. The reason for this cannot be
answered by the trial. One might, however, speculate
whether requiring the participants to take 20 capsules of
oil every day for 3 months, after first being reassured about
the good prognosis and encouraged to stay active, might
have confused the patients and strengthened their patient
identity. Alternatively, the prolonged sick leave might have
been a reaction to the disappointment of an improvement
that never came, or perhaps even a response to a slight
increase in symptoms in the seal oil group.
The trial did not include a control condition for BI, but
the previously established effectiveness of BI on RTW25,29,34
might imply that BI is difficult to outperform, and that
additional management of LBP may require more extensive
or alternative approaches. An avenue for future studies
could be to look at effective components of the BI, and
whether they can be enhanced.35 Another consideration
concerns the emerging interest in stratified care approaches
to LBP.36–38 Risk-based stratification, where treatment is
provided according to prognosis (low, medium, high), has
recently been demonstrated to improve disability outcomes,
including RTW.39 Further attempts to identify subgroups of
patients who might benefit from different treatment strat-
egies have also been made.36,40 Whether intervention strat-
egies guided by such screening procedures could produce
better disability outcomes could be a question for future
research to explore.
Key Points
Brief intervention programs are clinically
beneficial and cost-effective for patients with LBP.
TABLE 3 (Continued )
ITT
BI Mean
(95% CI)
BI and CBT
Mean (95% CI)
BI and Seal Oil
Mean (95% CI)
BI and Soy Oil
Mean (95% CI) Fy P
12 mo 2.42 (1.64–3.20) 1.68 (1.20–2.17) 2.10 (1.48–2.71) 2.23 (1.61–2.84) 1.13 0.34
Health-related quality of life (EQ5D)
Baseline 58.8 (55.6–61.9) 53.7 (50.2–57.2) 55.8 (52.3–59.3) 53.8 (50.2–57.4) 1.84 0.14
Baseline 58.5 (53.7–63.3) 58.3 (52.7–63.8) 58.8 (53.2–64.4) 54.8 (49.3–60.3) 0.54 0.65
3 mo 63.1 (58.5–67.7) 64.3 (58.8–69.7) 58.5 (53.7–63.2) 63.0 (58.2–67.8) 1.05 0.37
6 mo 65.1 (59.2–70.9) 69.8 (64.8–74.8) 63.0 (57.6–68.4) 61.6 (56.7–66.5) 1.96 0.12
12 mo 63.0 (58.3–67.7) 66.1 (61.5–70.7) 66.0 (61.8–70.1) 65.2 (61.2–69.2) 0.37 0.77
Values only for those who responded–all follow-ups (n¼154).
ydf¼3.
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Cognitive behavior therapy is one of the
recommended treatments for LBP, but until
now, evidence from randomized controlled trials
on RTW has been lacking.
Seal oil has previously been shown to have a
possible positive effect on muscle pain, but no
randomized controlled trials have so far been
carried out in a population of LBP patients.
Our study suggests that neither CBT nor seal oil
has any overall benefits over a brief cognitive
intervention program in LBP.
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